REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
Product
Disaggregation of Revenue [Line Items]
Revenue	493,348	393,840	1,516,533	1,348,279
Marketed by Company | Total net product revenues marketed by the Company
Disaggregation of Revenue [Line Items]
Revenue	464,302	369,460	1,425,778	1,245,762
Marketed by Company | Total net product revenues marketed by the Company | United States
Disaggregation of Revenue [Line Items]
Revenue	176,552	166,554	497,205	491,028
Marketed by Company | Total net product revenues marketed by the Company | Europe
Disaggregation of Revenue [Line Items]
Revenue	162,583	108,568	480,645	424,144
Marketed by Company | Total net product revenues marketed by the Company | Latin America
Disaggregation of Revenue [Line Items]
Revenue	60,791	38,958	213,246	140,911
Marketed by Company | Total net product revenues marketed by the Company | Rest of world
Disaggregation of Revenue [Line Items]
Revenue	64,376	55,380	234,682	189,679
Marketed by Sanofi | ALDURAZYME net product revenues marketed by Sanofi
Disaggregation of Revenue [Line Items]
Revenue	$ 29,046	$ 24,380	$ 90,755	$ 102,517